BioVie (BIVI) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioVie (BIVI) has outperformed Vyome (HIND) over the past year, losing 38.2% versus a loss of 75.9%. Over five years, BIVI leads with a -99.9% price change compared with -100.0% for HIND. BioVie is the larger company by market cap ($8.6 million vs $8.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | HIND |
|---|---|---|
| Share price | $0.80 | $1.20 |
| Market cap | $8.58M | $8.42M |
| 1-day change | -12.07% | -17.24% |
| YTD return | -31.03% | -65.12% |
| 1-year return | -38.22% | -75.90% |
| 5-year return | -99.87% | -100.00% |
| P/E ratio (TTM) | — | 0.25 |
| EPS (TTM) | $-2.85 | $4.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $319.71K |
| Revenue growth (YoY) | — | +24.43% |
| Net income (latest FY) | $-22.07M | $-10.26M |
| Gross margin | — | 68.43% |
| Operating margin | — | -3269.35% |
| Net margin | — | -3209.75% |
| 52-week high | $3.79 | $5.88 |
| 52-week low | $0.7515 | $1.20 |
| Distance from 52-week high | -78.89% | -79.59% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +557.50% | +635.83% |
| Average volume | 568.61K | 13.92K |
| Shares outstanding | 10.72M | 7.02M |
| Employees | 13 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed HIND by 37.7 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
BIVI vs HIND FAQ
Which is bigger, BioVie or Vyome?
BioVie (BIVI) is larger, with a market capitalization of $8.58M compared with $8.42M for Vyome (HIND).
Which stock has performed better over the past year, BIVI or HIND?
BIVI returned -38.22% over the past 12 months, compared with -75.90% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.